Key result
Streptokinase administration in patients with acute myocardial infarction was associated with significantly lower in-hospital mortality compared to no streptokinase (8.7% vs 20.5%, p=0.002).
Why the study?
Acute myocardial infarction is the leading cause of death and streptokinase is the most commonly used thrombolytic agent, motivating a comparison of in-hospital outcomes between patients receiving streptokinase and those not receiving it.
Does streptokinase reduce in-hospital mortality and complications in patients with acute myocardial infarction?
Observational (n=340)
No
Does streptokinase reduce in-hospital mortality and complications in patients with acute myocardial infarction?
Absolute Event Rate: 8.7% vs 20.5%
p-value: p=0.002
In patients with acute ST-elevation myocardial infarction, administration of streptokinase is associated with significantly lower in-hospital mortality and fewer complications compared to no reperfusion therapy.
Supports streptokinase evaluation in AMI; leaves open causal benefit and practice change without RCTs.
Introduction: Acute myocardial infarction is the leading cause of death. Streptokinase is the most commonly used thrombolytic agent. This study was conducted to compare in-hospital outcome of patients with acute myocardial infarction receiving streptokinase with those not receiving it. Materials & Methods: This descriptive observational study was conducted at Coronary Care Unit, North East Medical College Hospital from 1st July August 2016 to 30th June 2018. 340 patients having acute MI were in- cluded in the study. Two groups were formed: sk group receiving streptokinase and non-sk group not receiving. In-hospital mortality was the primary end point while mechanical and electrical complications were the secondary end points. Results: Among 340 patients, 255(75%) were males and 85(25%) females. Out of those 218 received strep-tokinase, while 122 did not. Mean age of sk group was 53.15±10.30 years and non-sk group 60.5±16 ears. Mean time of arrival to the hospital after symptom onset was 10.41±9.97 hours. SK group patients reached in 5.9±4.76 hours while non-sk group in 19.4±10.5 hours. In-hospital mortality in sk and non-sk group was 19(8.7%) and 25(20.5%) respectively, p=0.002. Complication rate was significantly higher in the non-sk group, 54.09% vs 34.86%, p=0.04. Conclusion: Patients of acute myocardial infarction receiving streptokinase have significantly lesser in-hospital mortality and complications as compared to patients not receiving it. Medicine Today 2019 Vol.31(2): 68-71
No takes yet. Share an insight, caveat, or question.
Uddin et al. (2019) conducted an observational in Acute myocardial infarction (n=340). Streptokinase vs. No streptokinase was evaluated on In-hospital mortality (p=0.002). Streptokinase administration in patients with acute myocardial infarction was associated with significantly lower in-hospital mortality compared to no streptokinase (8.7% vs 20.5%, p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: